Base de dados : MEDLINE
Pesquisa : D04.210.500.054.079.500 [Categoria DeCS]
Referências encontradas : 2022 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 203 ir para página                         

  1 / 2022 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452419
[Au] Autor:Joshi S; Rajasekaran K; Williamson J; Kapur J
[Ad] Endereço:Department of Neurology, University of Virginia, Charlottesville, Virginia, U.S.A.
[Ti] Título:Neurosteroid-sensitive δ-GABA receptors: A role in epileptogenesis?
[So] Source:Epilepsia;58(3):494-504, 2017 03.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: We determined the role of the neurosteroid-sensitive δ subunit-containing γ-aminobutyric acid A receptors (δ-GABARs) in epileptogenesis. METHODS: Status epilepticus (SE) was induced via lithium pilocarpine in adult rats, and seizures were assessed by continuous video-electroencephalography (EEG) monitoring. Finasteride was administered to inhibit neurosteroid synthesis. The total and surface protein expression of hippocampal δ, α4, and γ2 GABAR subunits was studied using biotinylation assays and Western blotting. Neurosteroid potentiation of the tonic currents of dentate granule cells (DGCs) was measured by whole-cell patch-clamp technique. Finally, the effects of inhibiting N-methyl-d-aspartate receptors (NMDARs) during SE on the long-term plasticity of δ-GABARs, neurosteroid-induced modulation of tonic current, and epileptogenesis were studied. RESULTS: The inhibition of neurosteroid synthesis 4 days after SE triggered acute seizures and accelerated the onset of chronic recurrent spontaneous seizures (epilepsy). The down-regulation of neurosteroid-sensitive δ-GABARs occurred prior to the onset of epilepsy, whereas an increased expression of the γ2-GABAR subunits occurred after seizure onset. MK801 blockade of NMDARs during SE preserved the expression of neurosteroid-sensitive δ-GABARs. NMDAR blockade during SE also prevented the onset of spontaneous seizures. SIGNIFICANCE: Changes in neurosteroid-sensitive δ-GABAR expression correlated temporally with epileptogenesis. These findings raise the possibility that δ-GABAR plasticity may play a role in epileptogenesis.
[Mh] Termos MeSH primário: Epilepsia do Lobo Temporal/fisiopatologia
Neurotransmissores/fisiologia
Receptores de GABA-A/fisiologia
Estado Epiléptico/fisiopatologia
[Mh] Termos MeSH secundário: Animais
Western Blotting
Giro Denteado/fisiopatologia
Modelos Animais de Doenças
Maleato de Dizocilpina/farmacologia
Regulação para Baixo/efeitos dos fármacos
Regulação para Baixo/fisiologia
Eletroencefalografia/efeitos dos fármacos
Feminino
Finasterida/farmacologia
Hipocampo/fisiopatologia
Compostos de Lítio
Masculino
Plasticidade Neuronal/efeitos dos fármacos
Plasticidade Neuronal/fisiologia
Neurônios/efeitos dos fármacos
Neurônios/fisiologia
Neurotransmissores/antagonistas & inibidores
Técnicas de Patch-Clamp
Pilocarpina
Ratos
Ratos Sprague-Dawley
Receptores de N-Metil-D-Aspartato/antagonistas & inibidores
Gravação em Vídeo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Lithium Compounds); 0 (Neurotransmitter Agents); 0 (Receptors, GABA-A); 0 (Receptors, N-Methyl-D-Aspartate); 01MI4Q9DI3 (Pilocarpine); 57GNO57U7G (Finasteride); 6LR8C1B66Q (Dizocilpine Maleate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13660


  2 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453908
[Au] Autor:Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
[Ad] Endereço:Endocrinology Unit, Maggiore-Bellaria Hospital, Medical Department, Azienda-Usl Bologna, Bologna, Italy.
[Ti] Título:Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
[So] Source:Andrology;5(4):671-678, 2017 07.
[Is] ISSN:2047-2927
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Despite their efficacy in the treatment of benign prostatic hyperplasia, the popularity of inhibitors of 5α-reductase (5ARIs) is limited by their association with adverse sexual side effects. The aim of this study was to review and meta-analyze currently available randomized clinical trials evaluating the rate of sexual side effects in men treated with 5ARIs. An extensive Medline Embase and Cochrane search was performed including the following words: 'finasteride', 'dutasteride', 'benign prostatic hyperplasia'. Only placebo-controlled randomized clinical trials evaluating the effect of 5ARI in subjects with benign prostatic hyperplasia were considered. Of 383 retrieved articles, 17 were included in this study. Randomized clinical trials enrolled 24,463 in the active and 22,270 patients in the placebo arms, respectively, with a mean follow-up of 99 weeks and mean age of 64.0 years. No difference was observed between trials using finasteride or dutasteride as the active arm considering age, trial duration, prostate volume or International Prostatic Symptoms Score at enrollment. Overall, 5ARIs determined an increased risk of hypoactive sexual desire [OR = 1.54 (1.29; 1.82); p < 0.0001] and erectile dysfunction [OR = 1.47 (1.29; 1.68); p < 0.0001]. No difference between finasteride and dutasteride regarding the risk of hypoactive sexual desire and erectile dysfunction was observed. Meta-regression analysis showed that the risk of hypoactive sexual desire and erectile dysfunction was higher in subjects with lower Q at enrollment and decreased as a function of trial follow-up. Conversely, no effect of age, low urinary tract symptom or prostate volume at enrollment as well as Q at end-point was observed. In conclusion, present data show that the use of 5ARI significantly increases the risk of erectile dysfunction and hypoactive sexual desire in subjects with benign prostatic hyperplasia. Patients should be adequately informed before 5ARIs are prescribed.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/efeitos adversos
Dutasterida/efeitos adversos
Disfunção Erétil/induzido quimicamente
Finasterida/efeitos adversos
Hiperplasia Prostática/tratamento farmacológico
Disfunções Sexuais Psicogênicas/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Idoso
Disfunção Erétil/fisiopatologia
Seres Humanos
Libido/efeitos dos fármacos
Masculino
Meia-Idade
Ereção Peniana/efeitos dos fármacos
Hiperplasia Prostática/enzimologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Risco
Comportamento Sexual/efeitos dos fármacos
Disfunções Sexuais Psicogênicas/fisiopatologia
Disfunções Sexuais Psicogênicas/psicologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 57GNO57U7G (Finasteride); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1111/andr.12353


  3 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29356110
[Au] Autor:Abdelmaksoud A
[Ad] Endereço:Mansoura Dermatology, Venereology and Leprosy Hospital, Mansoura, Egypt.
[Ti] Título:Comment on "Hidradenitis suppurativa in children treated with finasteride-A case series".
[So] Source:Pediatr Dermatol;35(1):158, 2018 01.
[Is] ISSN:1525-1470
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Finasterida
Hidradenite Supurativa
[Mh] Termos MeSH secundário: Criança
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
57GNO57U7G (Finasteride)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180123
[St] Status:MEDLINE
[do] DOI:10.1111/pde.13334


  4 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29197368
[Au] Autor:Chung MS; Bae WJ; Choi SW; Lee KW; Jeong HC; Bashraheel F; Jeon SH; Jung JW; Yoon BI; Kwon EB; Oh HA; Hwang SY; Kim SW
[Ad] Endereço:Department of Urology, Catholic Kwandong University, International St. Mary's Hospital, Incheon, Republic of Korea.
[Ti] Título:An Asian traditional herbal complex containing Houttuynia cordata Thunb, Perilla frutescens Var. acuta and green tea stimulates hair growth in mice.
[So] Source:BMC Complement Altern Med;17(1):515, 2017 Dec 02.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Houttuynia cordata Thunb (HC) is a traditional herbal medicine widely used in Asia for the treatment of patients with alopecia, usually in combination with other two herbal medicines (Perilla frutescens var. acuta (PFVA) and green tea (GT)). However, the effect of this herbal complex has not been clearly demonstrated. We sought to determine the hair growth-promoting effect of this herbal complex (HC, PFVA, and GT) in the animal model. METHODS: Six-week-old male C57BL/6 mice were randomly divided into four groups (negative control, finasteride (1 mg/kg) as a positive control, and two (200 and 400 mg/kg) concentrations of the herbal complex as experimental groups) and were fed its corresponding medications orally for 25 days. Hair growth was evaluated visually and microscopically. Western blot analysis for insulin-like growth factor (IGF)-1 and transforming growth factor (TGF)-ß1 was performed. RESULTS: The herbal complex exhibited hair growth-promoting activity in C57BL/6 mice. Grossly, the area of hair regrowth was 55.1 (±3.8) %, 70.2 (±6.3) % and 83.5 (±5.7) % in negative control, herbal complex 200 mg/kg and 400 mg/kg group, respectively. In histologic examination, the hair follicle count in deep subcutis was 2.6 (±0.7), 5.8 (±0.7) and 8.6 (±1.2) and the diameter of hair follicles was 11.9 (±5.0) µm, 17.4 (±3.9) µm and 22.8 (±5.2) µm in negative control, herbal complex 200 and 400 mg/kg group, respectively. The expression of IGF-1 was 0.14 (±0.01), 0.23 (±0.02) and 0.24 (±0.01) and the expression of TGF-ß1 was 0.26 (±0.01), 0.19 (±0.02) and 0.15 (±0.01) in negative control, the 200 and 400 mg/kg group, respectively. CONCLUSIONS: This data provides adequate preliminary experimental evidence to support the hair regeneration effect of this herbal complex.
[Mh] Termos MeSH primário: Medicamentos de Ervas Chinesas/farmacologia
Cabelo/efeitos dos fármacos
Houttuynia
Perilla frutescens
Chá
[Mh] Termos MeSH secundário: Animais
Finasterida/farmacologia
Folículo Piloso/efeitos dos fármacos
Masculino
Camundongos
Camundongos Endogâmicos C57BL
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal); 0 (Tea); 57GNO57U7G (Finasteride)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171204
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-017-2003-x


  5 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29187470
[Au] Autor:Chen CC; Huang CP; Tsai YT; Hseih TF; Shyr CR
[Ad] Endereço:Sex Hormone Research Center, Departments of Medical Laboratory Science and Biotechnology and Urology, Graduate Institute of Clinical Medical Science, China Medical University and Hospital, Taichung, Taiwan, R.O.C.
[Ti] Título:The Genomic Alterations of 5α-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer.
[So] Source:Anticancer Res;37(12):6893-6898, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Since androgens affect urothelial bladder cancer (UBC), we examined whether 5α-reductases (5-AR) have genomic alterations in UBC and whether 5α-reductase inhibitors (5-ARI) affect UBC. MATERIALS AND METHODS: The cBioPortal was used to analyze genomic alternations of 5-ARs in UBC cancer genomic datasets. Next, we used the Taiwan National Health Insurance Research database to conduct a population-based case-control study to investigate the effect of a 5-ARI, finasteride on UBC incidence. We also performed an XTT assay to examine the direct effect of finasteride on UBC cells. RESULTS: We found that 5-AR genomic alternations were observed in 29% of UBC patients and patients with alternations had shorter disease-free survival. Also, the use of finasteride with >180 cDDDs reduced the risk of UBC. Finasteride could directly inhibit UBC cell growth. CONCLUSION: Based on our findings, we concluded that 5-AR could be explored as a therapeutic target for UBC with 5-ARIs.
[Mh] Termos MeSH primário: 3-Oxo-5-alfa-Esteroide 4-Desidrogenase/metabolismo
Finasterida/uso terapêutico
Genômica/métodos
Neoplasias da Bexiga Urinária/tratamento farmacológico
[Mh] Termos MeSH secundário: Inibidores de 5-alfa Redutase/uso terapêutico
Idoso
Idoso de 80 Anos ou mais
Estudos de Casos e Controles
Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Sobrevivência Celular/genética
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Modelos Logísticos
Masculino
Meia-Idade
Neoplasias da Bexiga Urinária/genética
Neoplasias da Bexiga Urinária/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 57GNO57U7G (Finasteride); EC 1.3.99.5 (3-Oxo-5-alpha-Steroid 4-Dehydrogenase)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  6 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28804873
[Au] Autor:Holmes S; Harries M
[Ad] Endereço:Alan Lyell Centre for Dermatology, Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow, G51 4TF, U.K.
[Ti] Título:Re: Frontal Fibrosing Alopecia Severity Index (FFASI): a call for a more inclusive and globally relevant severity index for frontal fibrosing alopecia: reply from the authors.
[So] Source:Br J Dermatol;177(3):884, 2017 09.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Alopecia
Finasterida
[Mh] Termos MeSH secundário: Fibrose
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
57GNO57U7G (Finasteride)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.15796


  7 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28739284
[Au] Autor:García-García M; Sánchez-Hernández M; García-Hernández MP; García-Ayala A; Chaves-Pozo E
[Ad] Endereço:Sección de Microscopía, Servicio de Apoyo a la Investigación Regional, Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Murcia 30100, Spain.
[Ti] Título:Role of 5α-dihydrotestosterone in testicular development of gilthead seabream following finasteride administration.
[So] Source:J Steroid Biochem Mol Biol;174:48-55, 2017 Nov.
[Is] ISSN:1879-1220
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In teleosts, spermatogenesis is regulated by pituitary gonadotropins and sex steroids. 5α-dihydrotestosterone (DHT), derived from testosterone (T) through the action of 5α-reductase, has recently been suggested to play a physiologically important role in some fish species. In this study, gilthead seabream, Sparus aurata L., males received an implant of 1µgT/g body mass (bm) or vehicle alone and, 7days later, 1mg finasteride (FIN, an inhibitor of 5α-reductase)/kg bm or vehicle. Serum levels of T, 11-ketotestosterone (11KT), DHT and 17ß-estradiol (E ), and the mRNA levels of the main enzymes involved in their synthesis, were analysed. T promoted a transient increase in the serum levels of T, 11KT and E but a decrease in those of DHT at day 15 following T injection, in accordance with the up-regulation of mRNA levels of the enzymes involved in T transformation to 11KT (coding genes: cyp11b1 and hsd11b) and the down-regulation of mRNA levels of the enzyme responsible for T transformation to DHT (coding gene: srd5a). Interestingly, a similar effect was observed when FIN was injected. However, when fish were injected with T and FIN successively (T+FIN), control levels were not recovered at the end of the experimental period (28days). DHT seems to regulate E serum levels via the down-regulation of mRNA levels of aromatase (coding gene: cyp19a1a), which is needed for the transformation of T into E . The testis histology, together with the proliferative rates recorded upon T, FIN or T+FIN treatment, suggests that DHT is involved in the onset of the meiotic phase of spermatogenesis.
[Mh] Termos MeSH primário: 3-Oxo-5-alfa-Esteroide 4-Desidrogenase/genética
Inibidores de 5-alfa Redutase/farmacologia
Androgênios/farmacologia
Di-Hidrotestosterona/sangue
Finasterida/farmacologia
Testosterona/farmacologia
[Mh] Termos MeSH secundário: 11-beta-Hidroxiesteroide Desidrogenase Tipo 1/genética
Androgênios/sangue
Animais
Aromatase/genética
Estradiol/sangue
Proteínas de Peixes/genética
Masculino
Dourada
Esteroide 11-beta-Hidroxilase/genética
Testículo/efeitos dos fármacos
Testículo/crescimento & desenvolvimento
Testosterona/análogos & derivados
Testosterona/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 0 (Androgens); 0 (Fish Proteins); 08J2K08A3Y (Dihydrotestosterone); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); 57GNO57U7G (Finasteride); EC 1.1.1.146 (11-beta-Hydroxysteroid Dehydrogenase Type 1); EC 1.14.14.1 (Aromatase); EC 1.14.15.4 (Steroid 11-beta-Hydroxylase); EC 1.3.99.5 (3-Oxo-5-alpha-Steroid 4-Dehydrogenase)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE


  8 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28635053
[Au] Autor:Zou Y; Aboshora W; Li J; Xiao T; Zhang L
[Ad] Endereço:State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China.
[Ti] Título:Protective Effects of Lepidium meyenii (Maca) Aqueous Extract and Lycopene on Testosterone Propionate-Induced Prostatic Hyperplasia in Mice.
[So] Source:Phytother Res;31(8):1192-1198, 2017 Aug.
[Is] ISSN:1099-1573
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The inhibitory effect of maca extractant, lycopene, and their combination was evaluated in benign prostatic hyperplasia (BPH) mice induced by testosterone propionate. Mice were divided into a saline group, solvent control group and testosterone propionate-induced BPH mice [BPH model group, solvent BPH model group, benzyl glucosinolate group (1.44 mg/kg), maca group (60 mg/kg), lycopene treated (15, 5, and 2.5 mg/kg), maca (30 mg/kg) combine lycopene treated (7.5, 2.5, and 1.25 mg/kg), and finasteride treated]. Benzyl glucosinolate was used in order to evaluate its pharmacological activity on BPH to find out whether it is the major active component of maca aqueous extract. Finasteride was used as positive control. The compounds were administered once for 30 successive days. Compared with solvent BPH model group, BPH mice fed with maca (30 mg/kg) and lycopene (7.5 mg/kg) combination exhibited significant reductions in the prostatic index, prostatic acid phospatase, estradiol, testosterone, and dihydrotestosterone levels in serum. They also had similar histological compared with those aspects observed in the mice in the solvent control group. The results indicated that combination of maca and lycopene synergistically inhibits BPH in mice. Copyright © 2017 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Carotenoides/farmacologia
Lepidium/química
Extratos Vegetais/farmacologia
Hiperplasia Prostática/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Estradiol/sangue
Finasterida/farmacologia
Masculino
Camundongos
Camundongos Endogâmicos ICR
Hiperplasia Prostática/induzido quimicamente
Testosterona/sangue
Propionato de Testosterona
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Plant Extracts); 36-88-4 (Carotenoids); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); 57GNO57U7G (Finasteride); SB0N2N0WV6 (lycopene); WI93Z9138A (Testosterone Propionate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170622
[St] Status:MEDLINE
[do] DOI:10.1002/ptr.5838


  9 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28586548
[Au] Autor:Dlova NC; Dadzie OE
[Ad] Endereço:Dermatology Department, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
[Ti] Título:Frontal Fibrosing Alopecia Severity Index (FFASI): a call for a more inclusive and globally relevant severity index for frontal fibrosing alopecia.
[So] Source:Br J Dermatol;177(3):883-884, 2017 09.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Alopecia
Finasterida
[Mh] Termos MeSH secundário: Fibrose
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
57GNO57U7G (Finasteride)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170607
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.15694


  10 / 2022 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28408350
[Au] Autor:Melcangi RC; Santi D; Spezzano R; Grimoldi M; Tabacchi T; Fusco ML; Diviccaro S; Giatti S; Carrà G; Caruso D; Simoni M; Cavaletti G
[Ad] Endereço:Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. Electronic address: roberto.melcangi@unimi.it.
[Ti] Título:Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients.
[So] Source:J Steroid Biochem Mol Biol;171:229-235, 2017 Jul.
[Is] ISSN:1879-1220
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Recent reports show that, in patients treated with finasteride for male pattern hair loss, persistent side effects including sexual side effects, depression, anxiety and cognitive complaints may occur. We here explored the psychiatric and andrological features of patients affected by post-finasteride syndrome (PFS) and verified whether the cerebrospinal fluid (CSF) and plasma levels of neuroactive steroids (i.e., important regulators of nervous function) are modified. We found that eight out of sixteen PFS male patients considered suffered from a DSM-IV major depressive disorder (MDD). In addition, all PFS patients showed erectile dysfunction (ED); in particular, ten patients showed a severe and six a mild-moderate ED. We also reported abnormal somatosensory evoked potentials of the pudendal nerve in PFS patients with severe ED, the first objective evidence of a neuropathy involving peripheral neurogenic control of erection. Testicular volume by ultrasonography was normal in PFS patients. Data obtained on neuroactive steroid levels also indicate interesting features. Indeed, decreased levels of pregnenolone, progesterone and its metabolite (i.e., dihydroprogesterone), dihydrotestosterone and 17beta-estradiol and increased levels of dehydroepiandrosterone, testosterone and 5alpha-androstane-3alpha,17beta-diol were observed in CSF of PFS patients. Neuroactive steroid levels were also altered in plasma of PFS patients, however these changes did not reflect exactly what occurs in CSF. Finally, finasteride did not only affect, as expected, the levels of 5alpha-reduced metabolites of progesterone and testosterone, but also the further metabolites and precursors suggesting that this drug has broad consequence on neuroactive steroid levels of PFS patients.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/efeitos adversos
Transtorno Depressivo Maior/induzido quimicamente
Disfunção Erétil/induzido quimicamente
Finasterida/efeitos adversos
Pregnenolona/líquido cefalorraquidiano
Progesterona/líquido cefalorraquidiano
Testosterona/líquido cefalorraquidiano
[Mh] Termos MeSH secundário: Inibidores de 5-alfa Redutase/uso terapêutico
Adulto
Alopecia/tratamento farmacológico
Estudos de Casos e Controles
Transtorno Depressivo Maior/sangue
Transtorno Depressivo Maior/líquido cefalorraquidiano
Transtorno Depressivo Maior/epidemiologia
Manual Diagnóstico e Estatístico de Transtornos Mentais
Monitoramento de Medicamentos
Disfunção Erétil/epidemiologia
Disfunção Erétil/metabolismo
Disfunção Erétil/fisiopatologia
Potenciais Somatossensoriais Evocados/efeitos dos fármacos
Finasterida/uso terapêutico
Seres Humanos
Incidência
Itália/epidemiologia
Estudos Longitudinais
Masculino
Pregnenolona/sangue
Progesterona/análogos & derivados
Progesterona/sangue
Estudos Prospectivos
Escalas de Graduação Psiquiátrica
Nervo Pudendo/efeitos dos fármacos
Nervo Pudendo/fisiopatologia
Neuralgia do Pudendo/induzido quimicamente
Neuralgia do Pudendo/epidemiologia
Neuralgia do Pudendo/metabolismo
Neuralgia do Pudendo/fisiopatologia
Índice de Gravidade de Doença
Testosterona/análogos & derivados
Testosterona/sangue
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 3XMK78S47O (Testosterone); 4G7DS2Q64Y (Progesterone); 57GNO57U7G (Finasteride); 73R90F7MQ8 (Pregnenolone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170718
[Lr] Data última revisão:
170718
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170415
[St] Status:MEDLINE



página 1 de 203 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde